82982
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 6
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.401630375
- umap2_2d
- 1.909976848
- umap1_3d
- 0.778357613
- umap2_3d
- -0.438668607
- umap3_3d
- -0.334070469
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.340
- PANCREAS_BETA_CELLS+0.330
- G2M_CHECKPOINT+0.270
- SPERMATOGENESIS+0.260
- MYOGENESIS+0.130
- E2F_TARGETS+0.120
- ESTROGEN_RESPONSE_LATE+0.070
- BILE_ACID_METABOLISM+0.050
- COAGULATION+0.050
- ESTROGEN_RESPONSE_EARLY+0.040
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.660
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.580
- PROTEIN_SECRETION-0.560
- DNA_REPAIR-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- ADIPOGENESIS-0.490
- MTORC1_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG189 | — | — | 0.922 |
| 2 | MNG225 | — | — | 0.917 |
| 3 | MNG1003 | — | — | 0.915 |
| 4 | MDT-AP-1190 | Med | Medulloblastoma | 0.899 |
| 5 | MNG598 | — | — | 0.897 |
| 6 | MNG1131 | — | — | 0.895 |
| 7 | MNG555 | — | — | 0.895 |
| 8 | BS_YMAJC22S | low-grade glioma | — | 0.893 |
| 9 | MDT-AP-3189 | Med | Medulloblastoma | 0.892 |
| 10 | BS_23W9EPFE | Ganglioglioma | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |